Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders.
The initiative marks a significant expansion of Silo Pharma's therapeutic focus, which includes stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio already features programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
Ibogaine, a naturally occurring psychoactive alkaloid found in plants of the Apocynaceae family, has been studied for its potential in treating addiction and other neurological conditions. By targeting TBI and PTSD, Silo Pharma aims to address underserved conditions with significant unmet medical needs. Traumatic brain injury affects millions worldwide, often leading to long-term cognitive and psychiatric issues, while PTSD is a debilitating condition that can arise from traumatic events.
The provisional patent application underscores Silo's commitment to protecting its intellectual property and advancing novel therapies. This move could position the company at the forefront of ibogaine-based treatments for neurological and psychiatric disorders. For more details, the full press release can be accessed at https://ibn.fm/HdWHG.
Investors and stakeholders can stay updated on Silo Pharma's latest news through the company's newsroom at https://ibn.fm/SILO. About BioMedWire, the platform that distributed this news, is a specialized communications platform focused on the latest developments in the biotechnology, biomedical sciences, and life sciences sectors. It is part of the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution, and corporate communications solutions.
The importance of this announcement lies in its potential to open new therapeutic avenues for TBI and PTSD, conditions that currently have limited effective treatment options. If successful, Silo Pharma's ibogaine-based therapeutics could offer hope to millions of patients and create significant value for the company and its shareholders.
